Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials

BACKGROUND: Guidelines suggest that the serum carbohydrate antigen (CA19-9) level should be used when deciding on neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (hereafter referred to as pancreatic cancer). In patients with resectable pan...

Descripción completa

Detalles Bibliográficos
Autores principales: Doppenberg, Deesje, van Dam, Jacob L, Han, Youngmin, Bonsing, Bert A, Busch, Olivier R, Festen, Sebastiaan, van der Harst, Erwin, de Hingh, Ignace H, Homs, Marjolein Y V, Kwon, Wooil, Lee, Mirang, Lips, Daan J, de Meijer, Vincent E, Molenaar, I Quintus, Nuyttens, Joost J, Patijn, Gijs A, van Roessel, Stijn, van der Schelling, George P, Suker, Mustafa, Versteijne, Eva, de Vos-Geelen, Judith, Wilmink, Johanna W, van Eijck, Casper H J, van Tienhoven, Geertjan, Jang, Jin-Young, Besselink, Marc G, Groot Koerkamp, Bas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480034/
https://www.ncbi.nlm.nih.gov/pubmed/37440421
http://dx.doi.org/10.1093/bjs/znad210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480034/
https://www.ncbi.nlm.nih.gov/pubmed/37440421
http://dx.doi.org/10.1093/bjs/znad210

Ejemplares similares